EMEA-001794-PIP02-16-M02

Key facts

Active substance
Vamorolone
Therapeutic area
Other
Decision number
P/0032/2020
PIP number
EMEA-001794-PIP02-16-M02
Pharmaceutical form(s)
Oral suspension
Condition(s) / indication(s)
Treatment of Duchenne muscular dystrophy
Route(s) of administration
Oral use
Contact for public enquiries
ReveraGen BioPharma Ltd

Tel. +1 3017627980
E-mail: info@reveragen.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating